Single-Domain Antibody Theranostics on the Horizon

Overview

Journal J Nucl Med

Specialty Nuclear Medicine

Date 2022 Jul 14

PMID 35835579

Authors

Weijun Wei

Muhsin H Younis

Xiaoli Lan

Jianjun Liu

Weibo Cai

Affiliations

Soon will be listed here.

Abstract

Single-domain antibody (sdAb) is among the most promising vectors for developing molecular imaging tracers. Several sdAb tracers targeting human epidermal growth factor receptor 2 or programmed death ligand 1 have entered clinical practice. However, radiolabeled single-valent sdAbs generally have high kidney retention, limiting their therapeutic applications. Therefore, engineering strategies such as PEGylation or incorporation of renal cleavable linkers can be adapted to improve pharmacokinetics and reduce kidney retention. In this Focus on Molecular Imaging review, we try to summarize the latest developments in sdAb-derived agents and propose potential strategies that can be used to improve the theranostic value of radiolabeled sdAbs.

Citing Articles

Efficacy of radiolabelled PD-L1-targeted nanobody in predicting and evaluating the combined immunotherapy and chemotherapy for resectable non-small cell lung cancer.

Zhou X, Yan S, Ma X, Zhu H, Liu B, Yang X Eur J Nucl Med Mol Imaging. 2025; .

PMID: 39912938 DOI: 10.1007/s00259-025-07115-3.

Development of FAP-targeted theranostics discovered by next-generation sequencing-augmented mining of a novel immunized VNAR library.

Gunaratne G, Gallant J, Ott K, Broome P, Celada S, West J bioRxiv. 2025; .

PMID: 39868181 PMC: 11761682. DOI: 10.1101/2025.01.13.632555.

Utility of I-HLX58-Der for the Precision Treatment: Evaluation of a Preclinical Radio-Antibody-Drug-Conjugate Approach in Mouse Models.

Liu Y, Wang X, Zhang N, He S, Zhang J, Xu X Int J Nanomedicine. 2025; 20():723-739.

PMID: 39839455 PMC: 11748935. DOI: 10.2147/IJN.S501689.

Trends in nanobody radiotheranostics.

Long X, Cheng S, Lan X, Wei W, Jiang D Eur J Nucl Med Mol Imaging. 2025; .

PMID: 39800806 DOI: 10.1007/s00259-025-07077-6.

Molecular imaging of renal cell carcinomas: ready for prime time.

Wu Q, Shao H, Zhai W, Huang G, Liu J, Calais J Nat Rev Urol. 2024; .

PMID: 39543358 DOI: 10.1038/s41585-024-00962-z.

References

van Lith S, Huizing F, Franssen G, Hoeben B, Lok J, Doulkeridou S . Novel VHH-Based Tracers with Variable Plasma Half-Lives for Imaging of CAIX-Expressing Hypoxic Tumor Cells. Mol Pharm. 2022; 19(10):3511-3520. PMC: 9533306. DOI: 10.1021/acs.molpharmaceut.1c00841. View

Li D, Cheng S, Zou S, Zhu D, Zhu T, Wang P . Immuno-PET Imaging of Zr Labeled Anti-PD-L1 Domain Antibody. Mol Pharm. 2018; 15(4):1674-1681. DOI: 10.1021/acs.molpharmaceut.8b00062. View

Puttemans J, Stijlemans B, Keyaerts M, Vander Meeren S, Renmans W, Fostier K . The Road to Personalized Myeloma Medicine: Patient-specific Single-domain Antibodies for Anti-idiotypic Radionuclide Therapy. Mol Cancer Ther. 2021; 21(1):159-169. PMC: 9398099. DOI: 10.1158/1535-7163.MCT-21-0220. View

Kruwel T, Nevoltris D, Bode J, Dullin C, Baty D, Chames P . In vivo detection of small tumour lesions by multi-pinhole SPECT applying a (99m)Tc-labelled nanobody targeting the Epidermal Growth Factor Receptor. Sci Rep. 2016; 6:21834. PMC: 4766429. DOI: 10.1038/srep21834. View

Wei W, Jiang D, Ehlerding E, Luo Q, Cai W . Noninvasive PET Imaging of T cells. Trends Cancer. 2018; 4(5):359-373. PMC: 6034116. DOI: 10.1016/j.trecan.2018.03.009. View

Arano Y . Renal brush border strategy: A developing procedure to reduce renal radioactivity levels of radiolabeled polypeptides. Nucl Med Biol. 2020; 92:149-155. DOI: 10.1016/j.nucmedbio.2020.03.001. View

Varasteh Z, Mohanta S, Li Y, Armbruster N, Braeuer M, Nekolla S . Targeting mannose receptor expression on macrophages in atherosclerotic plaques of apolipoprotein E-knockout mice using Ga-NOTA-anti-MMR nanobody: non-invasive imaging of atherosclerotic plaques. EJNMMI Res. 2019; 9(1):5. PMC: 6340911. DOI: 10.1186/s13550-019-0474-0. View

Rashidian M, Keliher E, Bilate A, Duarte J, Wojtkiewicz G, Jacobsen J . Noninvasive imaging of immune responses. Proc Natl Acad Sci U S A. 2015; 112(19):6146-51. PMC: 4434737. DOI: 10.1073/pnas.1502609112. View

Langbein T, Weber W, Eiber M . Future of Theranostics: An Outlook on Precision Oncology in Nuclear Medicine. J Nucl Med. 2019; 60(Suppl 2):13S-19S. DOI: 10.2967/jnumed.118.220566. View

10.

de Veirman K, Puttemans J, Krasniqi A, Ertveldt T, Hanssens H, Romao E . CS1-specific single-domain antibodies labeled with Actinium-225 prolong survival and increase CD8+ T cells and PD-L1 expression in Multiple Myeloma. Oncoimmunology. 2021; 10(1):2000699. PMC: 8583167. DOI: 10.1080/2162402X.2021.2000699. View

11.

Zhou Z, Meshaw R, Zalutsky M, Vaidyanathan G . Site-Specific and Residualizing Linker for F Labeling with Enhanced Renal Clearance: Application to an Anti-HER2 Single-Domain Antibody Fragment. J Nucl Med. 2021; 62(11):1624-1630. PMC: 8612331. DOI: 10.2967/jnumed.120.261446. View

12.

Keyaerts M, Xavier C, Heemskerk J, Devoogdt N, Everaert H, Ackaert C . Phase I Study of 68Ga-HER2-Nanobody for PET/CT Assessment of HER2 Expression in Breast Carcinoma. J Nucl Med. 2015; 57(1):27-33. DOI: 10.2967/jnumed.115.162024. View

13.

Wang C, Chen Y, Hou Y, Liu Q, Zhang D, Zhao H . ImmunoPET imaging of multiple myeloma with [Ga]Ga-NOTA-Nb1053. Eur J Nucl Med Mol Imaging. 2021; 48(9):2749-2760. DOI: 10.1007/s00259-021-05218-1. View

14.

Wei W, Zhang D, Wang C, Zhang Y, An S, Chen Y . Annotating CD38 Expression in Multiple Myeloma with [F]F-Nb1053. Mol Pharm. 2021; 19(10):3502-3510. DOI: 10.1021/acs.molpharmaceut.1c00733. View

15.

Rashidian M, Ploegh H . Nanobodies as non-invasive imaging tools. Immunooncol Technol. 2022; 7:2-14. PMC: 9216400. DOI: 10.1016/j.iotech.2020.07.001. View

16.

Duray E, Lejeune M, Baron F, Beguin Y, Devoogdt N, Krasniqi A . A non-internalised CD38-binding radiolabelled single-domain antibody fragment to monitor and treat multiple myeloma. J Hematol Oncol. 2021; 14(1):183. PMC: 8561907. DOI: 10.1186/s13045-021-01171-6. View

17.

Senders M, Hernot S, Carlucci G, van de Voort J, Fay F, Calcagno C . Nanobody-Facilitated Multiparametric PET/MRI Phenotyping of Atherosclerosis. JACC Cardiovasc Imaging. 2018; 12(10):2015-2026. PMC: 6461528. DOI: 10.1016/j.jcmg.2018.07.027. View

18.

Gainkam L, Huang L, Caveliers V, Keyaerts M, Hernot S, Vaneycken I . Comparison of the biodistribution and tumor targeting of two 99mTc-labeled anti-EGFR nanobodies in mice, using pinhole SPECT/micro-CT. J Nucl Med. 2008; 49(5):788-95. DOI: 10.2967/jnumed.107.048538. View

19.

Xavier C, Vaneycken I, DHuyvetter M, Heemskerk J, Keyaerts M, Vincke C . Synthesis, preclinical validation, dosimetry, and toxicity of 68Ga-NOTA-anti-HER2 Nanobodies for iPET imaging of HER2 receptor expression in cancer. J Nucl Med. 2013; 54(5):776-84. DOI: 10.2967/jnumed.112.111021. View

20.

Ackaert C, Smiejkowska N, Xavier C, Sterckx Y, Denies S, Stijlemans B . Immunogenicity Risk Profile of Nanobodies. Front Immunol. 2021; 12:632687. PMC: 7985456. DOI: 10.3389/fimmu.2021.632687. View